Opis działalności
Werewolf Therapeutics is a highly innovative company striving to redefine the cancer treatment landscape with potential best-in-class therapies. It develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. They invented proprietary PREDATOR™ protein engineering technology to design and engineer the future of immuno-oncology biotherapeutics for patients.
Zarząd & Rada nadzorcza
| CEO |
| Dan Hicklin |
| Zarząd |
| Tim Trost, Randi Isaacs, Chulani Karunatilake, Ellen Lubman, Cynthia Seidel-Dugan |
| Rada nadzorcza |
| Luke Evnin, Michael Atkins, Meeta Chatterjee, Derek DiRocco, Dan Hicklin, Alon Lazarus, Briggs W. Morrison, Mike Sherman |
Dane firmy
| Nazwa: |
Werewolf Therapeutics Inc |
| Adres: |
200 Talcott Avenue, 2nd Floor,Watertown, MA 02472 |
| Telefon: |
+1 617-952-0555 |
| Fax: |
- |
| E-mail: |
info@werewolftx.com
|
| Internet: |
https://werewolftx.com/ |
| Przemysł: |
Biotechnologia |
| Sektor: |
Biotechnologia |
| Podsektor: |
- |
| Koniec roku finansowego: |
31.12 |
| Free float: |
- |
| Data IPO: |
29.04.2021 |
Relacje inwestorskie
| Nazwa: |
Josh Rappaport |
| Telefon: |
+1 212-362-1200 |
| Fax: |
- |
| E-mail: |
IR@werewolftx.com
|
